Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ALIMERA SCIENCES INC | c11855e8vk.htm |
| EX-99.1 - EXHIBIT 99.1 - ALIMERA SCIENCES INC | c11855exv99w1.htm |
Exhibit 99.2
| Alimera Sciences, Inc. Selected Data from the FAME Study Webcast February 3, 2011 1 |
| ILUVIEN Demographics 2 |
| Patient Disposition Patient Disposition AE, adverse event; FAc, fluocinolone acetonide. 3 |
| Study, Laser, and Off-Protocol Treatments Off-Protocol Treatments Off-Protocol Treatments 4 |
| ILUVIEN Efficacy 5 |
| FAME Study Variable Primary Variable: Difference between treatment and control groups in percentage of patients with improved BCVA from baseline of 15 or more letters on the ETDRS eye chart 6 BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; FAME, Fluocinolone Acetonide in Diabetic Macular Edema. |
| ^15 Letter Increase in BCVA Full Analysis Set - Trial A Full Analysis Set - Trial A Full Analysis Set - Trial A 7 |
| ^15 Letter Increase in BCVA Full Analysis Set - Trial A Full Analysis Set - Trial A Full Analysis Set - Trial A 8 |
| ^15 Letter Increase in BCVA Full Analysis Set - Trial B Full Analysis Set - Trial B Full Analysis Set - Trial B 9 |
| ^15 Letter Increase in BCVA Full Analysis Set - Trial B Full Analysis Set - Trial B Full Analysis Set - Trial B 10 |
| ^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined 11 |
| ^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined 12 |
| ^15 Letter Increase in BCVA Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined 13 |
| ^15 Letter Increase in BCVA Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined 14 |
| ^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline 15 |
| ^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline 16 |
| ILUVIEN Safety 17 |
| Cataract Side Effects Phakic Patients at Baseline Only Phakic Patients at Baseline Only Phakic Patients at Baseline Only 18 |
| IOP Related Side Effects IOP Related Side Effects 19 |
| Additional Data and Analysis Additional data and analysis of the FAME Study will be presented by Peter Campochiaro, M.D., on February 12, 2011, at 1:40 p.m. at the Angiogenesis, Exudation and Degeneration 2011 Meeting in the Mandarin Oriental Hotel, Miami, FL. 20 |
| Alimera Sciences, Inc. Selected Data from the FAME Study Webcast February 3, 2011 21 |